-
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt , MD, MPH, MBA and Dipender Gill , MD, PhD join Cardiovascular Scientific Advisory Board – – Company nominates abdominal aortic aneurysm as […] Read More
-
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
NEW YORK , Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it […] Read More
-
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive […] Read More
-
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK , Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced […] Read More
-
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
NEW YORK , Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it […] Read More
-
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK , Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it […] Read More
-
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the […] Read More
-
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio , Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced […] Read More
-
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease […] Read More
-
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are […] Read More
